STOCK TITAN

Qiming funds disclose 4.4% Zai Lab (ZLAB) stake in amended 13G/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Qiming-related investment entities have filed an amended Schedule 13G reporting their ownership in Zai Lab Limited’s ordinary shares. QM11 Limited is shown as directly holding 48,883,643 ordinary shares, equal to 4.4% of the class, based on 1,119,628,030 shares outstanding as of December 31, 2025.

Those 48,883,643 ordinary shares consist of 280,680 American depositary shares and 46,076,843 ordinary shares. Qiming Venture Partners IV, L.P. is reported with shared beneficial ownership of 47,387,408 shares, or 4.2% of the class, while Qiming Managing Directors Fund IV, L.P. reports 1,496,235 shares, or 0.1%. The filing states that the reporting persons’ holdings represent ownership of 5 percent or less of the outstanding ordinary shares.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: Note to Row (5) (7) and (9): As of the date of this 13G/A filing, Qiming Corporate GP IV, Ltd. is the general partner of Qiming Managing Directors Fund IV, L.P. and Qiming GP IV, L.P. Qiming Managing Directors Fund IV, L.P. holds approximately 3.06% of the equity interest of QM11 Limited. Qiming GP IV, L.P. is the general partner of Qiming Venture Partners IV, L.P., which holds approximately 96.94% of the equity interest of QM11 Limited. QM11 Limited is the owner of 48,883,643 ordinary shares, which is consisted of 280,680 American depository shares ("ADSs") and 46,076,843 ordinary shares. Note to Row (11): The percentage is calculated based upon an aggregate of 1,119,628,030 ordinary shares outstanding as of December 31, 2025, which is based on the information disclosed by the Issuer as of December 31, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Note to Row (6) (8) and (9): As of the date of this 13G/A filing, Qiming Managing Directors Fund IV, L.P. holds approximately 3.06% of the equity interest of QM11 Limited, which is the owner of 48,883,643 ordinary shares, which is consisted of 280,680 ADSs and 46,076,843 ordinary shares. Note to Row (11): The percentage is calculated based upon an aggregate of 1,119,628,030 ordinary shares outstanding as of December 31, 2025, which is based on the information disclosed by the Issuer as of December 31, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Note to Row (6) (8) and (9): As of the date of this 13G/A filing, Qiming GP IV, L.P. is the general partner of Qiming Venture Partners IV, L.P., which owns approximately 96.94% of the equity interest of QM11 Limited, which is the owner of 48,883,643 ordinary shares, which is consisted of 280,680 ADSs and 46,076,843 ordinary shares. Note to Row (11): The percentage is calculated based upon an aggregate of 1,119,628,030 ordinary shares outstanding as of December 31, 2025, which is based on the information disclosed by the Issuer as of December 31, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Note to Row (6) (8) and (9): As of the date of this 13G/A filing, Qiming Venture Partners IV, L.P. holds approximately 96.94% of the equity interest of QM11 Limited, which is the owner of 48,883,643 ordinary shares, which is consisted of 280,680 ADSs and 46,076,843 ordinary shares. Note to Row (11): The percentage is calculated based upon an aggregate of 1,119,628,030 ordinary shares outstanding as of December 31, 2025, which is based on the information disclosed by the Issuer as of December 31, 2025.


SCHEDULE 13G




Comment for Type of Reporting Person: Note to Row (5) (7) and (9): As of the date of this 13G/A filing, QM11 Limited holds 48,883,643 ordinary shares of the Issuer, which is consisted of 280,680 ADSs and 46,076,843 ordinary shares. Note to Row (11): The percentage is calculated based upon an aggregate of 1,119,628,030 ordinary shares outstanding as of December 31, 2025, which is based on the information disclosed by the Issuer as of December 31, 2025.


SCHEDULE 13G



Qiming Corporate GP IV, Ltd.
Signature:/s/ Holan Lam
Name/Title:Holan Lam/Authorized Signatory
Date:02/13/2026
Qiming Managing Directors Fund IV, L.P.
Signature:/s/ Holan Lam
Name/Title:Holan Lam/Authorized Signatory
Date:02/13/2026
Qiming GP IV, L.P.
Signature:/s/ Holan Lam
Name/Title:Holan Lam/Authorized Signatory
Date:02/13/2026
Qiming Venture Partners IV, L.P.
Signature:/s/ Holan Lam
Name/Title:Holan Lam/Authorized Signatory
Date:02/13/2026
QM11 Limited
Signature:/s/ Holan Lam
Name/Title:Holan Lam/Authorized Signatory
Date:02/13/2026
Exhibit Information

Exhibit 99.1 Joint Filing Agreement, dated as of February 13, 2019 (incorporated by reference to Exhibit A to the Reporting Persons' Schedule 13G filed with the SEC on February 13, 2019) https://www.sec.gov/Archives/edgar/data/1704292/000095010319001958/dp102255_sc13ga-zai.htm

Zai Lab Limited

NASDAQ:ZLAB

ZLAB Rankings

ZLAB Latest News

ZLAB Latest SEC Filings

ZLAB Stock Data

2.24B
49.45M
Biotechnology
Pharmaceutical Preparations
Link
China
SHANGHAI